Erythropoietin: A potential drug in the management of diabetic neuropathy - 11/07/18
pages | 6 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | We explore the potential role of erythropoietin in diabetic neuropathy. |
• | We suggest a possible therapeutic use of erythropoietin in diabetic neuropathy. |
• | We conclude that it is necessary to elucidate the mechanism by which erythropoietin exerts a neuroprotective effect in diabetic neuropathy. |
Abstract |
Erythropoietin (EPO) is required for promoting the progress of erythroid differentiation. However, the discovery of EPO and the EPO receptor (EPOR) in the nervous system may contribute to new treatment strategies for the use of EPO in neurodegenerative disorders. Diabetic neuropathy is a neurodegenerative disease that affects a large proportion of diabetic patients and results in alterations in functionality, mood and sleep. The pathogenic mechanisms generating diabetic neuropathy involve: Schwannopathy, polyol pathway activity, advanced glycation end-products (AGEs) accumulation, protein kinase C (PKC) activity, increased hexosamine pathway flux, oxidative stress, nitric oxide and inflammation. In this sense, evidence from both clinical and experimental studies indicates that EPO may reverse diabetic neuropathy through an antioxidant action by decreasing pro-inflammatory cytokines, restoring Na+/K+-ATPase activity, and blocking the generation of pro-apoptotic proteins. The aim of this review is to discuss the neuroprotector effect of EPO on pathogenic mechanisms of diabetic neuropathy.
Le texte complet de cet article est disponible en PDF.Keywords : Erythropoietin, Diabetic neuropathy, Oxidative stress, Inflammation, Apoptosis
Plan
Vol 105
P. 956-961 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?